Nexa's pyrolytic thumb implant:
This article was originally published in Clinica
Executive Summary
Nexa Orthopedics has received US FDA 510(k) clearance to sell its pyrolytic carbon carpometacarpal implant (CMI) for relieving basal thumb joint pain associated with arthritis, while improving the thumb's range of motion and biomechanical function. The San Diego, California firm added the product to its portfolio following its recent acquisition of BioProfile, which according to Nexa, has been marketing products in Europe for "many years". Nexa claims to be the only company in the world that designs, manufactures and distributes orthopaedic implants made of pyrolytic carbon. The CMI's official US launch is scheduled to take place in September 2006 at the American Society for Surgery of the Hand meeting, in Washington, DC.
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.